Biological factors of response to erythropoiesis-stimulating agents in low/int-1 grade MDS

被引：0
|
作者：
Pawlikowska, P.
Kosmider, O. [1 ]
Park, S. [1 ]
Bardet, V. [1 ]
Kuhnowsky, F.
Pierre-Eugene, C.
Picard, F.
Viallon, V.
Viguie, F. [2 ]
Mayeux, P.
Lacombe, C. [1 ]
Porteu, F.
Dreyfus, F. [1 ]
Fontenay, M. [1 ]
机构：
[1] Univ Paris 05, Hop Cochin, APHP, INSERM,U567, Paris, France
[2] Univ Paris 05, Hotel Dieu, APHP, Paris, France
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷
关键词：
D O I：
10.1016/S0145-2126(09)70072-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S51 / S52
页数：2
相关论文
共 50 条
  • [41] Predictors of response to erythropoiesis-stimulating agents (ESA) in cancer patients: the role of baseline serum epoetin level
    Jaime Sanz Ortiz
    Clinical and Translational Oncology, 2008, 10 : 486 - 492
  • [42] Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial
    Saglimbene, Valeria
    Palmer, Suetonia C.
    Craig, Jonathan C.
    Ruospo, Marinella
    Nicolucci, Antonio
    Tonelli, Marcello
    Johnson, David
    Lucisano, Giuseppe
    Williams, Gabrielle
    Valentini, Miriam
    D'Alonzo, Daniela
    Pellegrini, Fabio
    Strippoli, Paolo
    Salomone, Mario
    Santoro, Antonio
    Maffei, Stefano
    Hegbrant, Joergen
    Tognoni, Gianni
    Strippoli, Giovanni F. M.
    PLOS ONE, 2017, 12 (03):
  • [43] Erythropoietic response to erythropoiesis-stimulating agents and outcome: should we give up the haemoglobin target approach?
    Locatelli, Francesco
    Del Vecchio, Lucia
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (07) : 2069 - 2071
  • [44] Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
    Antelo, Guadalupe
    Mangaonkar, Abhishek A.
    Coltro, Giacomo
    Buradkar, Ajinkya
    Lasho, Terra L.
    Finke, Christy
    Carr, Ryan
    Binder, Moritz
    Gangat, Naseema
    Al-Kali, Aref
    Elliott, Michelle A.
    King, Rebecca L.
    Howard, Matthew
    Melody, Megan E.
    Hogan, William
    Litzow, Mark R.
    Tefferi, Ayalew
    Fernandez-Zapico, Martin E.
    Komrokji, Rami
    Patnaik, Mrinal M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (03) : E104 - E108
  • [45] Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Groepper, Stephanie
    Jonasova, Anna
    Vey, Norbert
    Mufti, Ghulam J.
    Buckstein, Rena
    Mittelman, Moshe
    Platzbecker, Uwe
    Shpilberg, Ofer
    Ram, Ron
    del Canizo, Consuelo
    Gattermann, Norbert
    Ozawa, Keiya
    Zhong, Jim
    Seguy, Francis
    Hoenekopp, Albert
    Beach, C. L.
    Fenaux, Pierre
    BLOOD, 2014, 124 (21)
  • [46] EUROPEAN PATTERN AND IMPACT OF THE USE ERYTHROPOIETIC AGENTS (ESAS) IN LOW AND INT-1 RISK MDS WITH PROPENSITY SCORING TECHNIQUES IN OBSERVATIONAL LONGITUDINAL STUDIES.
    Garelius, H.
    Johnston, W.
    Van de Loosdrecht, A.
    Park, S.
    de Swart, L.
    Stauder, R.
    Symeonidis, A.
    Sanz, G.
    Cermak, J.
    Georgescu, O.
    Holm, M. Skov
    Germing, U.
    Fenaux, P.
    MacKenzie, M.
    Malcovati, L.
    Madry, K.
    Almeida, A. Medina
    Bowen, David
    de Witte, T.
    Smith, A.
    Hellstrom-Lind-berg, E.
    HAEMATOLOGICA, 2013, 98 : 87 - 88
  • [47] Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide
    S Park
    D Vassilieff
    V Bardet
    F Viguié
    F Dreyfus
    Leukemia, 2010, 24 : 1960 - 1962
  • [48] Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide
    Park, S.
    Vassilieff, D.
    Bardet, V.
    Viguie, F.
    Dreyfus, F.
    LEUKEMIA, 2010, 24 (11) : 1960 - 1962
  • [49] Effect of patient exclusion criteria on the efficacy of erythropoiesis-stimulating agents in patients with cancer-related anemia - Response
    Coiffier, B
    ONCOLOGIST, 2005, 10 (09): : 762 - 763
  • [50] Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants
    Aher, Sanjay M.
    Ohlsson, Arne
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (02):
12345